Erratum: Efficacy and Safety of Rimegepant 75 Mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial [Corrigendum]
- PMID: 39650209
- PMCID: PMC11625503
- DOI: 10.2147/JPR.S499096
Erratum: Efficacy and Safety of Rimegepant 75 Mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial [Corrigendum]
Abstract
[This corrects the article DOI: 10.2147/JPR.S453806.].
© 2024 Lipton et al.
Figures
Erratum for
-
Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial.J Pain Res. 2024 Jul 22;17:2431-2441. doi: 10.2147/JPR.S453806. eCollection 2024. J Pain Res. 2024. PMID: 39070853 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials